ArticleJournal of gastroenterology2010
Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population.
Article in Journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale.Journal of health, population, and nutrition · 2025Pooled it
- Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a systematic review and meta-analysis.BMJ open · 2024Pooled it
- Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions.Metabolites · 2026Review
- Association between metabolic syndrome and inflammatory bowel disease: a bidirectional two-sample Mendelian randomized study.Archives of medical science : AMS · 2026Article
- Cardiometabolic diseases in patients with inflammatory bowel disease: An evidence-based review.World journal of gastroenterology · 2025Review
- Evaluating the triglyceride-glucose index as a biomarker for inflammatory bowel disease risk: insights from a UK Biobank prospective study.Frontiers in immunology · 2025Article
- Prevalence of Metabolic Syndrome and Its Association with Cardiovascular Outcomes in Hospitalized Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2024Article
- Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases.International journal of molecular sciences · 2021Review
- Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.World journal of gastroenterology · 2019Observational
- Metabolic syndrome in hypertensive women in the age of menopause: a case study on data from general practice electronic health records.BMC medical informatics and decision making · 2018Article
- Article
- Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?Therapeutics and clinical risk management · 2017Article
- Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article.World journal of gastroenterology · 2016Review
- Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy.European journal of gastroenterology & hepatology · 2015Article
- Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.Digestive diseases and sciences · 2015Article
- Dietary management of IBD--insights and advice.Nature reviews. Gastroenterology & hepatology · 2015Review
- Metabolic syndrome frequency in inflammatory bowel diseases.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
- Epidemiology of metabolic syndrome in patients with inflammatory bowel disease: a population-level cohort study from the United States.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MS) is associated with an increased risk of cardiovascular disease. However, its prevalence in inflammatory bowel disease (IBD) patients remains largely unknown. This study was planned to determine the prevalence of MS in Japanese IBD patients.
methodsThe prevalence of MS among outpatients with IBD aged 18 or older was studied using the modified National Cholesterol Education Program Adult Treatment Panel III definition.
resultsA total of 107 quiescent IBD patients, including 76 ulcerative colitis (UC) patients and 31 Crohn's disease (CD) patients, were studied. Sufficient data were collected from a total of 102 patients. Prevalence of MS was significantly higher in UC (23.0%) patients compared to CD patients (7.1%). MS prevalence was substantially higher among male IBD patients (21.1%) compared to female IBD patients (12.9%), particularly in patients over 30 years of age. No difference was observed in the prevalence of MS between our IBD cohort and the general population in both males and females aged 40 years and older (P = 0.707 in males, P = 0.328 in females). IBD patients with MS were also older than those without (50.2 ± 15.0 vs. 38.0 ± 11.9 years, P = 0.013). In a logistic regression analysis, age was the statistically significant predictor of MS among IBD patients. The odds ratio (95% confidence interval) was 1.064 (1.017-1.114).
conclusionsPrevalence of metabolic syndrome in our IBD patients was comparable to that of the general population. Because age was the independent risk factor for developing MS, evaluation for MS is needed for elderly IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.